Introduction
The lung is a major target for metastases from various cancer types; and metastatic lung tumors treated with surgery are increasing as patients' survival improves due to recent advances in cancer treatment. 1, 2) Metastatic lung tumors are often found to be synchronously or metachronously multiple. 3) Such tumors are usually treated with limited resection procedures, such as wedge resections or a segmentectomies, to spare pulmonary function. However, in cases of proximally located tumors or multiple tumors in a lobe, pulmonary lobectomy is sometimes necessary to remove the whole tumors.
Pulmonary lobectomies for metastatic tumors are reportedly performed for 12%-54% of patients. [4] [5] [6] However, few reports have evaluated the use of pulmonary lobectomy for metastatic tumors. The purpose of this study was to investigate the clinical applicability of pulmonary lobectomies to treat metastatic lung tumors by comparing surgical results of patients who undergo lobectomies to those who undergo limited resections.
Patients and methods
We retrospectively reviewed the clinical records of 143 consecutive patients with metastatic lung tumors who underwent surgery from 2006 to 2012 in the Department of Surgery and Science, Kyushu University Hospital. Among them, we analyzed data sets of 100 patients who underwent surgery for their first metastatic lung tumors. These patients collectively underwent 69 wedge resections, 23 lobectomies, and eight segmentectomies. Generally no mediastinal lymph nodes dissection was performed in the lobectomies. The clinical diagnoses of metastatic pulmonary tumors were mainly determined by chest CT scans and/or FDG-PET before surgery, which were confirmed by pathological examination of resected tissue samples. Our institutional review board approved this retrospective study (Kyushu University, IRB No. 21-42).
Intergroup differences in patient characteristics, including age, sex and surgical procedure, were assessed using Student's t-test and the c 2 test. Survival curves were estimated using the Kaplan-Meier method and assessed by the log-rank test. Terminal events were defined as death from any cause. A prognostic analysis was further performed using the Cox proportional hazards model. Statistical differences were considered to be significant if P <0.05. All data were analyzed using StatView J5.
Results

Clinicopathological features of patients with metastatic lung tumors
Clinicopathological features of the patients with metastatic lung tumors are described in Table 1 . A third of patients had multiple tumors, including 12 with bilateral tumors. Thirty-one percent of patients had tumors originating from musculoskeletal tissue, including osteosarcoma, synovial sarcoma, liposarcoma, Ewing sarcoma and malignant fibrous histiocytoma. Other tumors had epithelial cell origins. Multivariate analysis using Cox regression hazard model found no clinicopathological factors included in the present study to be associated with survival after surgery ( Table 2) .
Differences in clinicopathological features and post-operative survival between the lobectomy and limited resection groups
Patients were divided into two groups according to surgical procedure; the lobectomy group, and-for those who underwent wedge resections or segmentectomiesthe limited resection group. The lobectomy group was more likely to be younger (P = 0.06), have larger tumors (P = 0.0004), to have multiple tumors (P = 0.049), and to have tumors of musculoskeletal origin (P = 0.043), than vs. lobectomy group 41%, P = 0.21). Post-operative complications in the lobectomy group were a cerebral infarction, a wound infection and a fever with unknown focus; whereas those in the limited resection group were a pulmonary atelectasis, a minimal pulmonary thrombosis, a wound infection, an acute musculitis and a fever with unknown focus. The two groups did not significantly differ in survival (lobectomy group vs limited surgery group, 3-year survival: 75.2% vs. 80.4%, P = 0.15), although the survival curve of lobectomy group went below that of limited resection group (Fig. 1) . Univariate survival analyses using the Cox regression hazard model were performed for the lobectomy group to detect possible factors that the limited resection group ( Table 3) . Post-operative morbidities were observed in 13% (3 out of 23 patients) of the lobectomy group, whereas they were in 6.5% (5 out of 77 patients) of the limited resection group, and did not significantly differ (P = 0.31). Neither group suffered post-operative mortality. Among all patients included in this study, clinical records of 17 out of the 23 lobectomy group patients and 60 out of the 77 limited resection group patients were available for detailed data of the postoperative treatments. Although there was no significant difference in the receiving rate of postoperative treatments, limited resection group tended to undergo any treatments (chemotherapy or chemoradiotherapy) after the pulmonary resection (limited resection group: 58% been established as a safe procedure, as the postoperative mortality rate and morbidity rates are reported to be about 1%-2% and 10%-20%, respectively. 7, 8) However, as pulmonary metastases often occur both synchronously and metachronously, limited resections, such as wedge resections or segmentectomies, are preferred to lobectomies for pulmonary metastases. For tumors located at the proximal lobe region or multiple tumors detected simultaneously in a pulmonary lobe, a pulmonary lobectomy is often inevitable to resect the tumors entirely. Reportedly, lobectomies were adopted for about 12%-54% of patients who developed pulmonary metastases. [4] [5] [6] In the present study, 23% of patients with initial pulmonary metastases underwent pulmonary lobectomies.
In the present study, most common metastatic tumors are of musculoskeletal origin followed by those from head and neck cancers and digestive tract cancers. These tumors often progress to pulmonary metastases which are subject to surgical treatments with curative intent. 9,10) Vidarsdottir, et al. reported that colorectal carcinoma, sarcoma and renal cell carcinoma were the three most common primary malignancies in their series. 11) In our series, patients with musculoskeletal metastases were younger (average ages: 39.8 years vs. 61 years), and had more multiple tumors than those with other metastases (musculoskeletal tumor vs. others: 48% vs. 26%). Lobectomies might be selected more often for musculoskeletal metastases because younger patients are considered better candidates for a less conservative procedure with a curative intent. affected patients' postoperative survival ( Table 4) . Among the analyzed factors, only post-operative morbidity was associated with post-operative survival. To review treatment for new metastases that occurred after the initial pulmonary surgery, pulmonary resections were performed in eight of 17 patients (47%) who developed secondary lung tumors in the limited resection group, whereas no pulmonary resection was used for the five patients who developed secondary lung tumors in the lobectomy group.
Discussion
Pulmonary lobectomy has been a standard procedure for the surgical treatment of primary lung cancer. It has We found no survival difference between the lobectomy and limited resection groups, although the lobectomy group included tumors with larger size and in greater numbers. As the lobectomy group had younger patients than the limited resection group, patients with better status may have been selected for lobectomies and these patients may have been treated with more aggressive systemic therapy. With regard to treatments after the first pulmonary surgery, no patients who developed secondary tumors in the lobectomy group underwent further pulmonary resection; whereas 47% of such patients in the limited resection group underwent pulmonary resection, which implies that repetitive surgical resection may be difficult to conduct for patients who previously underwent lobectomies.
In regard to procedural safety, postoperative morbidity rate was not significantly higher in the lobectomy group than the limited resection group, which means lobectomy is as safe as limited resection for metastatic lung tumors. However, post-operative morbidity was only associated with worse prognosis in the lobectomy group, which implies that post-operative complications may undermine appropriate treatment for the post-operative clinical course of these patients. Therefore, preventing the postoperative morbidity is crucial to achieve optimal long-term survival after pulmonary metastasectomy.
In conclusion, although the present study was a retrospective study with a small number of patients with various metastatic lung tumors, our results might indicate that lobectomy for pulmonary metastases is an applicable procedure in patients with better status received some adjuvant therapy for whom long-term survival is expected after the surgery.
Disclosure Statement
None.
